Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487934 | 1.00 | MAPT (0.30) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL4724633 | 0.80 | SRD5A1 (0.36) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL5621592 | 0.80 | CASP1 (0.41) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL4722731 | 0.80 | SRD5A1 (0.36) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL4791976 | 0.80 | SRD5A1 (0.36) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL4761270 | 0.80 | CASP1 (0.41) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL9075055 | 0.79 | HTT (0.31) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL9075051 | 0.79 | HTT (0.31) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL9075058 | 0.79 | HTT (0.31) | MAPTMEN1NPC1ALDH1A1NFKB1 | |
| SCHEMBL13790132 | 0.77 | HTT (0.33) | MAPTMEN1NPC1ALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | MAPT 521/4885MEN1 829/4885NPC1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.